Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.
| dc.contributor.author | Hill, Nathan R | |
| dc.contributor.author | Lasserson, Daniel | |
| dc.contributor.author | Thompson, Ben | |
| dc.contributor.author | Perera-Salazar, Rafael | |
| dc.contributor.author | Wolstenholme, Jane | |
| dc.contributor.author | Bower, Peter | |
| dc.contributor.author | Blakeman, Thomas | |
| dc.contributor.author | Fitzmaurice, David | |
| dc.contributor.author | Little, Paul | |
| dc.contributor.author | Feder, Gene | |
| dc.contributor.author | Qureshi, Nadeem | |
| dc.contributor.author | Taal, Maarten | |
| dc.contributor.author | Townend, Jonathan | |
| dc.contributor.author | Ferro, Charles | |
| dc.contributor.author | McManus, Richard | |
| dc.contributor.author | Hobbs, F D Richard | |
| dc.date.accessioned | 2024-03-04T14:03:59Z | |
| dc.date.available | 2024-03-04T14:03:59Z | |
| dc.date.issued | 2022-12-12 | |
| dc.identifier.citation | Hill NR, Lasserson D, Thompson B, Perera-Salazar R, Wolstenholme J, Bower P, Blakeman T, Fitzmaurice D, Little P, Feder G, Qureshi N, Taal M, Townend J, Ferro C, McManus R, Hobbs FDR. Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials. 2022 Dec 12;23(1):999. doi: 10.1186/s13063-022-06972-9. Erratum for: Trials. 2014 May 08;15:160. | en_US |
| dc.identifier.eissn | 1745-6215 | |
| dc.identifier.doi | 10.1186/s13063-022-06972-9 | |
| dc.identifier.pmid | 36510220 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14200/3850 | |
| dc.description.abstract | None available | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | BMC | en_US |
| dc.relation.url | https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06972-9 | en_US |
| dc.title | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. | en_US |
| dc.type | Corrigendum | |
| dc.source.journaltitle | Trials | |
| dc.source.volume | 23 | |
| dc.source.issue | 1 | |
| dc.source.beginpage | 999 | |
| dc.source.endpage | ||
| dc.source.country | England | |
| rioxxterms.version | NA | en_US |
| dc.contributor.trustauthor | Townend, John | |
| dc.contributor.trustauthor | Ferro, Charles | |
| dc.contributor.department | Cardiology | en_US |
| dc.contributor.department | Renal Medicine | en_US |
| dc.contributor.role | Medical and Dental | en_US |
| oa.grant.openaccess | na | en_US |